Werewolf Therapeutics enters $15M upfront license deal with Jazz for WTX-613 (IFNα INDUKINE)

Werewolf Therapeutics, Inc.

Upfront payment of $15M within 10 days of signing; Jazz to reimburse pre-clinical costs.
Eligible for up to $520M in development/regulatory milestones and up to $740M in sales-based milestones.
Tiered mid-single-digit royalties on annual net sales of licensed products.
Werewolf grants Jazz worldwide exclusive license to patent rights for IFNα variants, including WTX-613.
Jazz responsible for IND submission and all subsequent development and commercialization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.